Finch Therapeutics Group Valuation
| FNCHDelisted Stock | USD 8.51 0.19 2.18% |
At this time, the firm appears to be fairly valued. Finch Therapeutics shows a prevailing Real Value of $8.22 per share. The current price of the firm is $8.51. Our model computes the value of Finch Therapeutics from reviewing the firm fundamentals such as Shares Owned By Institutions of 11.35 %, shares owned by insiders of 53.48 %, and Current Valuation of 10.74 M as well as analyzing its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Finch Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Finch Therapeutics is based on 3 months time horizon. Increasing Finch Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Finch Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Finch Pink Sheet. However, Finch Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 8.51 | Real 8.22 | Hype 8.51 |
The intrinsic value of Finch Therapeutics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Finch Therapeutics' stock price.
Estimating the potential upside or downside of Finch Therapeutics Group helps investors to forecast how Finch pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Finch Therapeutics more accurately as focusing exclusively on Finch Therapeutics' fundamentals will not take into account other important factors: Finch Therapeutics Total Value Analysis
Finch Therapeutics Group is currently forecasted to have valuation of 10.74 M with market capitalization of 1.94 M, debt of 30.13 M, and cash on hands of 104.67 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Finch Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
10.74 M | 1.94 M | 30.13 M | 104.67 M |
Finch Therapeutics Investor Information
About 53.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.14. Some equities with similar Price to Book (P/B) outperform the market in the long run. Finch Therapeutics recorded a loss per share of 6.59. The entity had not issued any dividends in recent years. The firm had 1:30 split on the 12th of June 2023. Based on the key indicators related to Finch Therapeutics' liquidity, profitability, solvency, and operating efficiency, Finch Therapeutics Group is not in a good financial situation at this time. It has a very high probability of going through financial hardship in February.Finch Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Finch Therapeutics has an asset utilization ratio of 0.15 percent. This signifies that the Company is making $0.001507 for each dollar of assets. An increasing asset utilization means that Finch Therapeutics Group is more efficient with each dollar of assets it utilizes for everyday operations.Finch Therapeutics Ownership Allocation
Finch Therapeutics Group retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.Finch Therapeutics Profitability Analysis
The company reported the previous year's revenue of 107 K. Net Loss for the year was (74.75 M) with loss before overhead, payroll, taxes, and interest of (57.03 M).About Finch Therapeutics Valuation
An absolute valuation paradigm, as applied to Finch Pink Sheet, attempts to find the value of Finch Therapeutics based on its fundamental and basic technical indicators. By analyzing Finch Therapeutics's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Finch Therapeutics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Finch Therapeutics. We calculate exposure to Finch Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Finch Therapeutics's related companies.Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts. Finch Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 189 people.
8 Steps to conduct Finch Therapeutics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Finch Therapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Finch Therapeutics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Finch Therapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Finch Therapeutics' revenue streams: Identify Finch Therapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Finch Therapeutics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Finch Therapeutics' growth potential: Evaluate Finch Therapeutics' management, business model, and growth potential.
- Determine Finch Therapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Finch Therapeutics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Finch Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 1.6 M |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Other Consideration for investing in Finch Pink Sheet
If you are still planning to invest in Finch Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Finch Therapeutics' history and understand the potential risks before investing.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |